Compare Visa Inc (V) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Zimmer Biomet Holdings Inc — how do they compare? Visa Inc trades at $360.38 (market cap $671.74B), while Zimmer Biomet Holdings Inc trades at $95.52 (market cap $18.55B). The key difference: Visa Inc is far larger — about 36.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| V | ZBH | |
|---|---|---|
Market Cap | $671.74B | $18.55B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $370.47 | $107.71 |
52-Week Low | $295.52 | $79.58 |
Enterprise Value | $682.32B | $25.61B |
Dividend Yield | 0.74% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
